You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

    SBC: BIOPEPTIDES CORP            Topic: NIAID

    DESCRIPTION (provided by applicant): Caused by Borrelia burgdorferi, Lyme Disease (LD) can affect the skin, heart, joints or nervous system leading to an array of symptoms that overlap with those of other illnesses. LD is the most common vector-borne infectious disease in the United States and remains a significant public health concern. Early diagnosis and treatment is key to improving disease ou ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  2. PalmStat: a self-contained point of care diagnostic platform

    SBC: Synectic Engineering, Inc            Topic: NIAID

    DESCRIPTION (provided by applicant): Point of care testing is a test that is performed near or at the site of care. In addition it has come to imply a rapid turnaround time, ease of use and convenience for the patient. Traditional Point of Care single usecartridge tests are lateral flow immunoassay tests where the capture antibody is labeled with a chromagen, which allows for a positive reaction t ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  3. Nitric Oxide-Releasing Intranasal Gel To Decolonize Biofilm-embedded S. Aureus

    SBC: Novan, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): Staphylococcus aureus is the second leading cause of hospital-acquired bloodstream infections. In 2003, nearly 300,000 patients in US hospitals acquired an S. aureus infection, which accounted for nearly three million days of hospitalization, 9.5 billion in excess costs, and at least 12,000 inpatient deaths. Additionally, approximately 50% of the US population ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  4. Safe and Efficacious Oral MIF Inhibitors for Rheumatoid Arthritis Treatment

    SBC: INNOVIMMUNE BIOTHERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): There are high unmet medical needs in the limited biologic therapeutics for 1.0% of adults with rheumatoid arthritis [RA] associated with staggering 39.2 billion annual US health care and societal costs. These are dueto inadequate efficacy; patient's inconvenience, prohibitive costs, poor adherence and treatment discontinuations; manufacturing risks and s ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  5. Electrical System for Rapid Bacterial Cultures

    SBC: TECHSHOT, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The broad, long-term objective of the proposed project Electrical System for Rapid Bacterial Cultures is to develop an automated electrical impedance analyzer for measuring bacterial growth in contaminated blood. Thepurpose of the System is to hasten the time to diagnose sepsis from 1-2 days down to a few hours. The specific aims of the project are to (1) bui ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  6. Preventing Burn Wound Infection Using a Novel Free Radical Sterilization System

    SBC: GOLKOWSKI CZESLAW            Topic: NIAID

    DESCRIPTION (provided by applicant): Approximately two million burn injury cases require medical attention on a yearly basis in the United States alone, with 20,000 of these cases requiring admission to specialized burn centers. One of the foremost causesof morbidity and mortality in the burn patient is infection. Indeed, for those patients with burn size greater than 40% of total body surface are ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  7. A transfollicular nanovaccine against leishmaniasis

    SBC: VINDICO NANOBIOTECHNOLOGY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The World Health Organization estimates that over 350 million people are at risk of developing leishmaniasis and infection prevalence is 14 million people in the world. Annually, 2 million people are infected with Leishmania species and 270,000 will die. Leishmaniasis is one of the most important parasitic diseases affecting the U.S. military today, with over 2 ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  8. Novel Metallo-beta-lactamase Inhibitors

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTION (provided by applicant): -lactam resistance conferred by zinc-based metallo- -lactamases (Amber Class B) is an emerging global health problem1-3. Members of this family of enzymes such as NDM-1 are found on mobile genetic elements which are rapidly spreading in Enterobacteriaceae and threaten to erode the future utility of the - lactam antibiotics (i.e. penicillins, cephalosporins, c ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. Therapeutic Antibodies for Rabies

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody to Respiratory Syncytial Virus (RSV) that is now bein ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Therapeutic Antibodies for Bacteria

    SBC: TRELLIS BIOSCIENCE, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Trellis Bioscience has developed its patented CellSpot technology into a robust platform for characterizing the secreted antibody from single human lymphocytes with regard to specificity and affinity against multiple antigens. For example, the platform was used to isolate a rare, high quality human antibody to Respiratory Syncytial Virus (RSV) that is now bein ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government